Welcome to our dedicated page for NHWK news (Ticker: NHWK), a resource for investors and traders seeking the latest updates and insights on NHWK stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NHWK's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NHWK's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NightHawk Biosciences (NYSE American: NHWK) has reported its strategic, financial, and operational updates for the year ended December 31, 2022. The company recognized $6.4 million in revenue, primarily from product sales of ANTHIM® to the Canadian government. However, it faced a net loss of $43.4 million, resulting in a loss per share of ($1.70). NightHawk is transitioning towards biodefense and biomanufacturing, investing in facilities in San Antonio and Kansas. As of December 31, 2022, it had $44.3 million in cash and equivalents, but an audit opinion raised concerns about its ability to continue as a going concern due to recurring losses.
